307 results on '"Reipert, Birgit M."'
Search Results
2. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A
3. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
4. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor
5. Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study
6. Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
7. Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector
8. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression
9. Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency
10. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors
11. IVIG induces apoptotic cell death in CD56dim NK cells resulting in inhibition of ADCC effector activity of human PBMC
12. Coagulation Factor Inhibitors: Diagnosis and Management
13. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A
14. Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study
15. B-cell memory against factor VIII
16. How Full-Length FVIII Benefits from Its Heterogeneity – Insights into the Role of the B-Domain
17. Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients
18. FVIII concentrate half-life heterogeneity in patients with haemophilia A is due to variability in endogenous VWF clearance.
19. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans
20. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs
21. Prospective hemophilia inhibitor PUP study reveals distinct antibody signatures during FVIII inhibitor eradication
22. Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages
23. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients
24. A Flow-Cytometry-Based Approach to Facilitate Quantification, Size Estimation and Characterization of Sub-visible Particles in Protein Solutions
25. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice
26. Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model
27. T cell–independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist
28. Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9
29. The soluble cytoplasmic tail of CD45 regulates T‐cell activation via TLR4 signaling
30. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development
31. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes
32. Development of a Transgenic Mouse Model with Immune Tolerance for Human Coagulation Factor VIIa
33. Comprehensive approach for identification of functional FCGR2C alleles resulting in protein expression as a determinant for predicting predisposition to autoimmunity
34. Induction of immune tolerance by oral IVIG
35. Immunology of Inhibitor Development
36. Models for assessing immunogenicity and efficacy of new therapeutics for the treatment of haemophilia
37. Blockade of the costimulatory CD28‐B7 family signal axis enables repeated application of AAV8 gene vectors
38. High-dose factor VIII inhibits factor VIII–specific memory B cells in hemophilia A with factor VIII inhibitors
39. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors
40. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders
41. AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies
42. The Factor VIII Variant X5 Enhances Hemophilia a Gene Therapy Efficiency By Its Improved Secretion
43. Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys
44. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays
45. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors
46. Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures
47. The Irish Personalized Approach to the Treatment of Haemophilia (iPATH) - Determinants of Inter-Individual Variation in FVIII Pharmacokinetics
48. Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms
49. Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)
50. Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.